Executive Summary
The treatment of obesity and metabolic disease has evolved rapidly over the past several years. Among the most significant advances in obesity medicine are glucagon-like peptide-1 (GLP-1) receptor agonists, commonly referred to as GLP-1 medications.
These therapies have demonstrated clinically meaningful benefits in appetite regulation, weight reduction, blood sugar management, and overall metabolic health. Historically, GLP-1 medications were available primarily as injectable therapies. Today, oral GLP-1 medications offer a convenient, needle-free alternative for many individuals.
Two of the most widely discussed oral GLP-1 medications in 2026 are Eli Lilly’s Foundayo™ (orforglipron) and Novo Nordisk’s Rybelsus® (semaglutide). Although both therapies target the GLP-1 receptor pathway, they differ in their active ingredients, administration requirements, approved uses, and clinical data.
This scientific review examines how oral GLP-1 medications work, compares Eli Lilly’s and Novo Nordisk’s oral GLP-1 therapies, and discusses effectiveness, dosing, side effects, and treatment considerations.
What Is GLP-1?
GLP-1, or Glucagon-Like Peptide-1, is a naturally occurring hormone produced by specialized cells in the intestines after eating.
GLP-1 helps regulate several important metabolic functions, including:
- Appetite and satiety
- Gastric emptying
- Blood sugar levels
- Insulin secretion
- Glucagon release
- Energy balance
- Body weight regulation
Because GLP-1 influences both appetite and glucose metabolism, scientists developed medications that mimic the effects of this naturally occurring hormone.
How Do GLP-1 Medications Work?
GLP-1 receptor agonists activate receptors throughout the body that are involved in appetite and glucose regulation.
Appetite Regulation
GLP-1 medications act on areas of the brain involved in hunger and satiety. As a result, many individuals experience increased feelings of fullness and reduced appetite.
Delayed Gastric Emptying
GLP-1 therapies slow the rate at which food leaves the stomach. This may help individuals:
- Feel fuller longer
- Reduce calorie intake
- Experience fewer hunger cravings
Blood Sugar Regulation
GLP-1 receptor agonists may:
- Increase insulin secretion when blood glucose levels rise
- Reduce glucagon production
- Improve post-meal blood sugar control
Weight Management Support
Through these combined mechanisms, GLP-1 therapies may support:
- Meaningful weight reduction
- Improved metabolic health markers
- Reduced waist circumference
- Better appetite management
Eli Lilly’s Oral GLP-1 Medication: Foundayo™ (Orforglipron)
Active Ingredient
Orforglipron
Orforglipron is the first approved non-peptide oral GLP-1 receptor agonist. Unlike peptide-based therapies, it is a small-molecule medication that does not require special absorption enhancers or fasting administration requirements.
Administration
- Oral tablet
- Once daily
- May be taken with or without food
- No water restrictions
- No fasting requirements
FDA Indication
Foundayo™ may be prescribed for adults with obesity or adults who are overweight and have at least one weight-related condition, including:
- High blood pressure
- Prediabetes
- Dyslipidemia
- Sleep apnea
Clinical Effectiveness
Phase 3 studies demonstrated average weight reductions approaching approximately 12% to 15% of starting body weight at certain doses.
Studies also reported improvements in:
- Waist circumference
- Blood pressure
- Certain cholesterol markers
- Metabolic health indicators
Individual responses vary.
Novo Nordisk’s Oral GLP-1 Medication: Rybelsus® (Semaglutide)
Active Ingredient
Semaglutide
Semaglutide is a peptide-based oral GLP-1 receptor agonist that has been extensively studied for blood sugar management and weight reduction.
FDA Indication
Rybelsus® is approved to:
- Improve blood sugar control in adults with Type 2 diabetes
- Reduce certain cardiovascular risks in eligible individuals with Type 2 diabetes
Administration
- Once daily
- Empty stomach
- With no more than four ounces of plain water
- Wait at least 30 minutes before eating, drinking, or taking other medications
Recommended Dosing
3 mg Once Daily
Treatment initiation dose.
7 mg Once Daily
Recommended maintenance dose.
14 mg Once Daily
May be prescribed if additional therapeutic benefit is needed.
Clinical studies have shown that FDA-approved oral semaglutide (Rybelsus® 7 mg and 14 mg) can produce modest weight loss, averaging approximately 5 to 10 pounds in adults with Type 2 diabetes. Higher investigational doses of oral semaglutide studied specifically for obesity have demonstrated substantially greater reductions in body weight, averaging approximately 13% to 17% over 64 to 68 weeks when combined with lifestyle modifications. Individual results may vary.
Clinical Effectiveness
Clinical studies demonstrated:
- Significant reductions in HbA1c
- Improvements in fasting blood glucose
- Meaningful reductions in body weight
- Improvements in certain cardiovascular risk markers
Results vary among individuals.
Comparison of Oral GLP-1 Medications
| Characteristic | Foundayo™ | Rybelsus® |
|---|---|---|
| Manufacturer | Eli Lilly and Company | Novo Nordisk A/S |
| Active Ingredient | Orforglipron | Semaglutide |
| Administration | Any time of day | Empty stomach |
| Food Restrictions | None | Yes |
| Water Restrictions | None | Yes |
| Dosing Frequency | Once daily | Once daily |
| Primary FDA Use | Weight Management | Type 2 Diabetes |
Common Side Effects of Oral GLP-1 Medications
The most commonly reported side effects include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Indigestion
- Fatigue
- Reduced appetite
These side effects are generally mild to moderate and frequently improve with continued treatment.
Important Safety Considerations
Oral GLP-1 medications are not appropriate for everyone.
Individuals should discuss their medical history with a licensed healthcare provider, particularly if they have:
- Personal or family history of Medullary Thyroid Carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis
- Gallbladder disease
- Kidney disease
- Other significant medical conditions
Frequently Asked Questions
What are the currently approved oral GLP-1 medications?
As of 2026, two of the most widely discussed oral GLP-1 medications are:
Foundayo™ (orforglipron) by Eli Lilly and Company, a non-peptide oral GLP-1 receptor agonist approved for chronic weight management in eligible adults with obesity or overweight and at least one weight-related medical condition.
Rybelsus® (semaglutide) by Novo Nordisk A/S, a peptide-based oral GLP-1 receptor agonist approved to improve blood sugar control in adults with Type 2 diabetes and to reduce certain cardiovascular risks in eligible individuals with Type 2 diabetes.
The approved uses, treatment goals, and administration requirements of these medications differ, and treatment decisions should always be individualized.
What is the newest oral GLP-1 medication?
Foundayo™ (orforglipron) is the first approved non-peptide oral GLP-1 receptor agonist indicated for chronic weight management.
Which oral GLP-1 medication may produce greater weight loss?
Current clinical evidence suggests that orforglipron may produce substantial weight reductions in eligible individuals. However, treatment decisions should be individualized based on a person’s medical history, treatment goals, and healthcare provider evaluation.
Are oral GLP-1 medications as effective as injectable medications?
Injectable GLP-1 therapies generally demonstrate greater average weight reduction. However, newer oral therapies are narrowing the gap while offering a convenient needle-free option.
How long does it take to notice results?
Some individuals experience appetite changes within several weeks. Meaningful weight reduction generally occurs over several months when medication is combined with healthy nutrition and lifestyle modifications.
Who may qualify for prescription GLP-1 medications?
Eligibility depends upon an individual’s medical history, current medications, body mass index, risk factors, and evaluation by a licensed healthcare provider.
The SabaRX™ Perspective
At SabaRX™, we believe that losing weight is only the beginning of a healthier future.
True wellness is about building a stronger, healthier body that supports you for decades to come. By focusing on preserving and building lean muscle mass, you can help maintain strength, mobility, metabolism, and independence as you age—so you can enjoy an active, vibrant lifestyle in your 50s, 60s, 70s, and beyond.
Long-term success often involves more than medication alone and may include:
- Healthier nutrition habits
• Adequate protein intake
• Hydration strategies
• Regular physical activity and strength training
• Wellness education
• Long-term behavioral support
Our philosophy is simple: Losing weight is important, but building strength, supporting your metabolism, and creating sustainable healthy habits are what help you live better—not just longer.
LOSE WEIGHT. PROTECT YOUR HEALTH. RECLAIM YOUR FUTURE.
SabaRX™ is a marketing, technology, and administrative platform that helps individuals explore medically supervised weight management options by connecting patients with independent licensed healthcare providers who determine whether treatment options, including GLP-1 therapies, may be clinically appropriate following an individualized medical evaluation.
To learn more about medically supervised weight management options, visit www.SabaRX.com.
References
- U.S. Food and Drug Administration. Rybelsus® (semaglutide) Prescribing Information.
- U.S. Food and Drug Administration. Foundayo™ (orforglipron) Prescribing Information.
- Eli Lilly and Company. FDA Approval Announcement for Foundayo™.
- Novo Nordisk A/S. Rybelsus® Prescribing Information and Dosing Guide.
- American Diabetes Association. Standards of Care in Diabetes—2026.
- American Association of Clinical Endocrinology. Clinical Practice Guidelines for Medical Care of Patients with Obesity.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1.
- Wilding JPH, et al. Long-Term Effects of GLP-1 Receptor Agonists on Weight Management and Metabolic Health. New England Journal of Medicine.
Disclaimer
This publication is provided solely for educational and informational purposes and does not constitute medical advice, diagnosis, treatment recommendations, or medical opinions. The SabaRX™ Research & Analysis Team develops educational content by reviewing publicly available scientific literature, FDA-approved prescribing information, clinical studies, and other reputable medical resources. The SabaRX™ Research & Analysis Team is not composed of practicing physicians and does not provide patient-specific healthcare guidance.
SabaRX™ is a marketing, technology, and administrative platform that connects individuals with independent licensed healthcare providers and pharmacy partners where available. SabaRX™ does not practice medicine, provide medical advice, diagnose medical conditions, prescribe or dispense medications, or direct patient care.
The medications, products, companies, trademarks, and trade names referenced in this publication, including but not limited to products and trademarks of Eli Lilly and Company and Novo Nordisk A/S, are the property of their respective owners. SabaRX™ is not affiliated with, sponsored by, endorsed by, or associated with Eli Lilly and Company, Novo Nordisk A/S, or any of their products, brands, or affiliates. References to third-party medications and companies are made solely for factual, scientific, comparative, and educational purposes.
Treatment decisions, medication eligibility, and healthcare recommendations are made solely by independent licensed healthcare providers following an appropriate medical evaluation. Individual results vary, and no health or weight-loss outcomes are guaranteed. In the event of a medical emergency, call 911 or seek immediate medical attention.
The SabaRX™ Research & Analysis Team develops educational content by reviewing publicly available scientific literature, peer-reviewed publications, FDA-approved prescribing information, clinical studies, and other reputable medical resources. The information presented in this publication is intended solely for educational and informational purposes.